---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-236343"
form_type: "8-K"
ticker: "ELV"
cik: "0001156039"
company_name: "Elevance Health, Inc."
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:21:48.463736+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Susan Dodson DeVore elected to Anthem board as independent director

## Summary
- Elected effective Aug 3, 2021; term expires at 2022 annual meeting; appointed to Audit and Finance Committees.
- DeVore recently retired as CEO and Director of Premier, Inc., a healthcare supply chain and technology company.
- She brings decades of finance, strategy, and healthcare consulting experience, including as a partner at Ernst & Young.
- She also serves on the board of UNUM Group.
- Board Chair Elizabeth Tallett says DeVore's leadership in driving innovation will provide valuable insights.

## SEC filing metadata
- accession: 0001193125-21-236343
- form_type: 8-K
- ticker: ELV
- cik: 0001156039
- company_name: Elevance Health, Inc.
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1156039/000119312521236343/0001193125-21-236343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1156039/000119312521236343/d169797d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-236343
- JSON: https://secwatch.observer/filing/0001193125-21-236343.json
- Plain text: https://secwatch.observer/filing/0001193125-21-236343.txt

## Key facts
- Executive change
  Susan Dodson DeVore was elected as independent director at Elevance Health, Inc..
  - Action: elected
  - Role: independent director
  source text: On August 3, 2021, the Board of Directors (the “Board”) of the Company elected Susan Dodson DeVore to serve as an independent director effective immediately, with a term expiring at the Company’s 2022 annual meeting of shareholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1156039/000119312521236343/0001193125-21-236343-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.